The relationship between the structure of dermatan sulfate derivatives and their antithrombotic activities.

[1]  M. Kyogashima,et al.  Dermatan Sulfate as a Bifunctional Antithrombotic , 2006 .

[2]  P. Antich,et al.  Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[3]  P. Mourão,et al.  Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. , 2005, Biochimica et biophysica acta.

[4]  D. Tollefsen,et al.  Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. , 2004, Blood.

[5]  M. Geng,et al.  Effects of dermatan sulfate derivatives on platelet surface P-selectin expression and protein C activity in blood of inflammatory bowel disease patients. , 2004, World journal of gastroenterology.

[6]  F. R. Melo,et al.  Structural composition and differential anticoagulant activities of dermatan sulfates from the skin of four species of rays, Dasyatis americana, Dasyatis gutatta, Aetobatus narinari and Potamotrygon motoro. , 2004, Biochimie.

[7]  L. Greenfield,et al.  New and Effective Treatment of Experimentally Induced Venous Thrombosis with Anti-inflammatory rPSGL-Ig , 2002, Thrombosis and Haemostasis.

[8]  J. Chung,et al.  Antiplatelet Activity of Green Tea Catechins Is Mediated by Inhibition of Cytoplasmic Calcium Increase , 2001, Journal of cardiovascular pharmacology.

[9]  F. Rosendaal,et al.  Increased soluble P‐selectin levels following deep venous thrombosis: cause or effect? , 2000, British journal of haematology.

[10]  José A Fernández,et al.  Dermatan Sulfate and LMW Heparin Enhance the Anticoagulant Action of Activated Protein C , 1999, Thrombosis and Haemostasis.

[11]  M. Kyogashima,et al.  Dermatan sulfate enhances the lysis of laser-induced thrombus in vivo. , 1998, Thrombosis research.

[12]  R. Linhardt,et al.  Dermatan sulfate as a potential therapeutic agent. , 1995, General pharmacology.

[13]  J. Millet,et al.  The Venous Antithrombotic Profile of Naroparcil in the Rabbit , 1994, Thrombosis and Haemostasis.

[14]  B. Boneu,et al.  Dermatan Sulfate Is a More Potent Inhibitor of Clot-bound Thrombin than Unfractionated and Low Molecular Weight Heparins , 1994, Thrombosis and Haemostasis.

[15]  G. Torri,et al.  Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate. , 1993, The Biochemical journal.

[16]  B. Boneu,et al.  Antithrombotic properties of a dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor II. , 1993, Blood.

[17]  F. Ofosu,et al.  The effects of heparin and dermatan sulphate on t-PA-induced thrombolysis and blood loss in rabbits , 1993 .

[18]  L. Rosenberg,et al.  Interaction of heparin cofactor II with biglycan and decorin. , 1993, The Journal of biological chemistry.

[19]  R L Jackson,et al.  Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. , 1991, Physiological reviews.

[20]  D. Tollefsen,et al.  Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. , 1990, The Journal of biological chemistry.

[21]  M. Colombi,et al.  The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and beta TG/PF4 release. , 1990, Thrombosis research.

[22]  B. Boneu,et al.  A Simple Method to Measure Dermatan Sulfate at Sub-Microgram Concentrations in Plasma , 1988, Thrombosis and Haemostasis.

[23]  B. Boneu,et al.  Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties. , 1988, Thrombosis research.

[24]  M. Scully,et al.  Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II. , 1988, The Biochemical journal.

[25]  M. Donati,et al.  Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. , 1987, Blood.

[26]  D. Tollefsen,et al.  Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. , 1986, The Journal of biological chemistry.

[27]  D. Tollefsen,et al.  Activation of heparin cofactor II by dermatan sulfate. , 1983, The Journal of biological chemistry.

[28]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.

[29]  B. Lucchesi,et al.  Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury. , 2006, Thrombosis research.

[30]  B. Mulloy.  The specificity of interactions between proteins and sulfated polysaccharides. , 2005, Anais da Academia Brasileira de Ciencias.

[31]  S. Brister,et al.  Prevention and treatment of thrombosis: novel strategies arising from our understanding the healthy endothelium. , 1993, Wiener klinische Wochenschrift.

[32]  F. Ofosu,et al.  An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. , 1992, The Journal of clinical investigation.

[33]  A. Kuroiwa,et al.  Proteoglycan obtained from bovine aorta suppress thrombin-induced platelet aggregation. , 1992, Artery.

[34]  D. Hoppensteadt,et al.  Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin. , 1991, Seminars in thrombosis and hemostasis.